Renexxion Ireland Ltd
Pascal Druzgala has had an extensive career in the pharmaceutical industry. From 1997 to 2010, they held the position of Senior VP Research and CSO at ARYx Therapeutics. In this role, they were responsible for drug discovery and translational research activities and successfully brought four projects into clinical phase. These projects included Budiodarone, an anti-arrhythmic drug for atrial fibrillation, Naronapride, a gastro-prokinetic drug for gastroparesis, Tecarfarin, an anticoagulant for preventing blood clots and strokes associated with atrial fibrillation, and ATI-9242, an antipsychotic drug for schizophrenia.
Following their time at ARYx Therapeutics, Druzgala joined Optivia Biotechnology as Executive VP and CSO from 2011 to 2013. Pascal then moved on to Armetheon, Inc. where they served as EVP and CSO from 2012 to 2019. Most recently, in 2020, Druzgala took on the role of Chief Scientific Officer at Renexxion Ireland Ltd. Overall, Druzgala's work experience demonstrates their expertise and leadership in the pharmaceutical industry, particularly in drug discovery and development.
Pascal Druzgala obtained their Doctor of Pharmacy (Pharm.D.) degree in the field of Pharmacy from Universite de Montpellier. Pascal attended the university from 1973 to 1978. Later, they pursued a PhD in Medicinal Chemistry from the University of Florida, graduating in the years 1982 to 1985.
This person is not in any teams
This person is not in any offices
Renexxion Ireland Ltd
Renexxion Ireland Innovation There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in a wide range of these disorders. It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required. Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).